Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax SA said underwriters fully exercised their option to buy 960,000 additional ADSs (15% of initial ADSs) in its U.S. offering of 6.4M ADSs. The company expects delivery with a July 6, 2026 closing. Total ADSs: 7.36M; gross proceeds about $920.0M (€807.4M) and estimated net about $874.1M (€767.1M). Proceeds will fund obefazimod commercialization plans, R&D (ulcerative colitis/Crohn’s), and general purposes.
How this was made
The 30-second read
Why it matters
The incremental 960,000 ADSs increase gross proceeds to ~$920M and expand funding intended for US commercialization expenses and Phase 3 R&D (ulcerative colitis and Crohn’s disease), with remainder for general corporate purposes.
Market read
A financing mechanics update (over-allotment fully exercised) with explicit proceeds and stated use, relevant for dilution/runway expectations into the offering close.
What to watch
Net proceeds are after underwriting commissions/expenses, and the offering price is tied to a VWAP window plus a fixed premium—watch for how ABVX trades relative to that pricing reference into the July 6 closing.
Background
Abivax is a clinical-stage biotech developing obefazimod (ABX464) for chronic inflammatory diseases; it recently launched a US ADS offering and now reports full exercise of the underwriters’ over-allotment option.
Ticker impact
Abivax says underwriters exercised the 15% over-allotment option, adding 960,000 ADSs and raising gross proceeds to about $920M.
Near-term pressure possible from dilution optics, partially offset by reduced financing risk from the larger proceeds; direction likely depends on how the market prices the offering vs. runway needs.
This is a primary financing update (ADS issuance size and proceeds) with explicit use-of-proceeds, but it does not include new clinical efficacy/regulatory milestones that would clearly re-rate the asset.
Market effects
Biotech financing conditions and investor appetite for clinical-stage immunology assets may be read through this larger-than-initial ADS raise.
Limited direct spillover beyond European/US biotech capital markets given the company-specific nature of the update.
Mostly company-specific; could marginally influence sentiment toward clinical-stage biotech funding in US and Europe.
Counterpoint
The over-allotment being fully exercised can be interpreted as strong underwriting demand, suggesting the market was willing to fund the company at the set premium.
Key entities
- CompanyAbivax SA
Clinical-stage biotech; announces full exercise of over-allotment option for additional ADSs and updated offering proceeds.
- Drug candidateobefazimod (ABX464)
Lead candidate in Phase 3 for ulcerative colitis; proceeds earmarked for commercialization and clinical R&D.
- Listing venueNasdaq Global Market (ADS ticker: ABVX)
ADS trading venue referenced for the offering and ticker symbol.
